Yonhap Infomax NewsMay 18
Samchundang Pharm returns to profitability in Q1 2026 with operating profit of 2.4 billion won driven by Eylea biosimilar sales, despite production disruptions from GMP inspections and Middle East logistics challenges affecting European exports
#YonhapInfomax #SamchundangPharm #EyleaBiosimilar #Q1Earnings #OperatingProfit #BiosimilarDivision #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=121003
Yonhap Infomax NewsMay 15, 2025
Celltrion Pharm achieves record Q1 revenue of 112.5 billion won, up 16% year-on-year, driven by strong growth in chemical and biosimilar divisions
#YonhapInfomax #CelltrionPharm #Q1Revenue #ChemicalDivision #BiosimilarDivision #OperatingProfit #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=63416
Celltrion Pharm Reports Record Q1 Revenue of 112.5 Billion Won, Up 16%

Celltrion Pharm achieves record Q1 revenue of 112.5 billion won, up 16% year-on-year, driven by strong growth in chemical and biosimilar divisions

Yonhap Infomax